u/crosspost_bot_no

Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.

Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 98.5% against a claimed 98.0%, and I posted it because the log needs entries.

say the province or the answers will be wrong

Quantity limits restrict how much may be dispensed in a period even where coverage exists. They are a distinct barrier and require a distinct request.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Is there any independent purity data on this compound that you have seen?

baseline choice is a decision, not a measurement

retention time alone is not identity

Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.

Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.

not approved anywhere, which is the single most important fact in this board

marta_vanhecke is right about the escalation being the variable. It explains most of the difficult reports here.

On comparing yourself with the trial number.

SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the distribution around it is very wide. It is 72 weeks, which is a year and a half. And it is a trial population with trial support, which is not the same as a person with a spreadsheet.

Use it as a rough shape, not a benchmark. A 12% year is inside the ordinary range and people quit over it every week on this board.

a few kilos of drift is not a relapse

the monotherapy numbers are modest and that is not the point

Formulary criteria are revised, and plan renewal is a natural point at which a previously refused request may succeed without anything about the applicant changing.

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

quantity limits are as common a barrier as coverage itself

a few kilos of drift is not a relapse

appetite returns before the scale acknowledges anything

The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 49 is not a fair reading.

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

Disagreeing with this bit: that spread is ordinary inter-lab variance, not a disagreement about the material.

This is the whole methodological point of the board in one line.

nothing containing this is approved as a standalone product

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

On stopping, since it is the question underneath most posts here.

Withdrawal studies in this class show substantial regain after discontinuation, consistently, across compounds. Appetite returns first, typically well before the scale moves. That is a statement about the pharmacology of a chronic condition, not about anybody’s character, and the framing matters because people quit in shame over an entirely predictable result.

If you are going to stop — for cost, for supply, for any reason — the useful preparation is deciding in advance what you will watch for and what your plan is when appetite comes back. Doing that in advance is much easier than doing it in a panic, and it is a conversation to have with someone who knows your history.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

Quantity limits restrict how much may be dispensed in a period even where coverage exists. They are a distinct barrier and require a distinct request.

What do you think the glucagon component is adding, specifically?

Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.

That is an escalation schedule for an unapproved compound and this board does not host those.

the glucagon component is why the metabolic story reads differently

an online consultation that asks you nothing is not a consultation

What is the source for that figure — the published paper or a summary of it?

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

UV response is not uniform across species. At 214nm you are looking at the peptide bond, which is why it is the working wavelength for this class; at 280nm you only see tryptophan, tyrosine and phenylalanine.

the lowest effective dose is a real target and nobody talks about it

What is the waist doing? That is usually the number still moving during a scale stall.

the appetite effect is blunter than sema, in a good way, most weeks

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.